MedTrace Logo

Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)

NCT00567723 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2105

Last updated 2021-03-17

No results posted yet for this study

Summary

Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients with no lanthanum exposure and to patients being treated for hyperphosphatemia with any marketed product.

Conditions

  • Hyperphosphatemia

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-25
Primary Completion
2016-06-07
Completion
2016-06-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00567723 on ClinicalTrials.gov